The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both ... to win expanded insurance coverage for Wegovy. Last year, Wegovy won approval in the U.S. for use ...

The Centers for Medicare and Medicaid Services (CMS) listed Ozempic ... last year after its diabetes medication NovoLog was selected. The company said it “remains opposed to government price ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

including Ozempic and Wegovy — the blockbuster diabetes and weight loss drugs. The drugs have faced public backlash over their high price, fueling demand for cheaper alternatives. The list, which ...

WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and ... make a prescription last longer.” That brings the total to 25 drugs that will have lower price tags for Medicare ...